Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's Chantix for smoking cessation: Labeling for Pfizer's newly approved selective nicotinic acetylcholine receptor partial agonist Chantix (varenicline) for smoking cessation includes superiority claims over GlaxoSmithKline's Zyban (bupropion). In one study, 44% of Chantix patients were abstinent in treatment weeks nine through 12 compared to 30% of Zyban patients and 17% on placebo, labeling says. Additionally, 29% of Chantix patients were continuously abstinent through the end of treatment compared to 23% of Zyban patients. On May 10, Chantix (formerly Champix) became the first nicotine agonist approved by FDA and the first new prescription medication approved for smoking cessation in nearly a decade. Roll-out of the tablet therapy is slated for the second half of the year...
You may also be interested in...
Pfizer anti-smoking agent EU approval
European authorities approve Pfizer's novel smoking agent varenicline Sept. 26 under the trade name Champix. Varenicline was approved in the U.S. May 10 under the trade name Chantix (1Pharmaceutical Approvals Monthly May 2006, p. 5). Pfizer had sought to use the Champix name in the U.S. as well, but FDA review documents said the name was "overly fanciful and overstates the efficacy of the product" (2Pharmaceutical Approvals Monthly July 2006, p. 27)...
MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011